Labixiaoxin Snacks Group (SEHK:1262) Returns To Profit In 1H 2025 Challenging Bearish Narratives

Labixiaoxin Snacks Group (SEHK:1262) has opened FY 2025 with first half revenue of C¥516 million and basic EPS of C¥0.01, while trailing twelve month figures show revenue of C¥969.8 million and basic EPS of C¥0.05. This points to a shift from losses reported in 2024. Over recent periods, revenue has moved from C¥493.8 million in 1H 2024 to C¥372.9 million in 2H 2024 and then to C¥516 million in 1H 2025. Over the same spans, EPS has moved from losses of C¥0.33 and C¥0.23 per share in 1H and 2H 2024 to a small profit in the latest half. This sets up a story where investors will be watching how much of that early earnings recovery flows through to margins.

See our full analysis for Labixiaoxin Snacks Group.

With the headline numbers on the table, the next step is to set these results against the narratives that investors follow to see which stories hold up and which get pushed into question.

Curious how numbers become stories that shape markets? Explore Community Narratives

Profit Swing to C¥2.5 Million in 1H 2025

• Net income moved from losses of C¥43.6 million in 1H 2024 and C¥49.8 million in 2H 2024 to a profit of C¥2.5 million in 1H 2025, while trailing twelve month net income reached C¥11.9 million.
• What stands out for a bullish view is that this C¥2.5 million half year profit and C¥11.9 million trailing twelve month profit come after several loss making periods. This strongly supports the idea of a turnaround but also sits alongside a five year annualized earnings trend of 15.7% decline, so any bullish thesis has to balance the recent shift into profit against that longer record.

High Quality Earnings, Weak Interest Cover

• Trailing twelve month earnings are described as high quality, yet interest payments are flagged as not well covered by those earnings. This means the current profit level of C¥11.9 million is small relative to financing costs.
• Bears focus on that weak interest coverage as a key financial risk and the data supports that caution, because even after becoming profitable over the last year the company is still reported to have earnings that do not comfortably cover interest. The recent move into profit does not on its own resolve concerns about financial strain.

P/E at 57.8x Versus 14.1x Industry

• The shares trade on a P/E of 57.8x compared with about 14.1x for the Hong Kong food industry and 5.5x for peers, so the valuation multiple is roughly 4x the industry average and more than 10x the peer average based on trailing earnings.
• What is striking for a bearish view is that this very high P/E multiple sits against trailing twelve month net income of only C¥11.9 million and a five year annualized earnings decline of 15.7%, so critics argue the share price at C¥3.57 builds in expectations that are far ahead of the recent profit record.

To see how other investors are framing this mix of rich valuation, fresh profitability and balance sheet risk, check out what the community is saying about Labixiaoxin Snacks Group Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Labixiaoxin Snacks Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With a mix of fresh profit, a rich P/E and balance sheet questions, the story is clearly split. Check the data, weigh both sides and see what stands out to you in the 1 key reward and 1 important warning sign

See What Else Is Out There

Labixiaoxin Snacks Group combines a relatively high 57.8x P/E and weak interest coverage with a five year annualized earnings decline of 15.7%, which keeps risk firmly on the table.

If you want to balance that kind of pressure on earnings quality and debt costs, compare it with companies screened for stronger cushions using the 265 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com